Ocugen Alternatives & Competitors
12 companies similar to Ocugen — Approaching healthcare innovation with purpose and agility to deliver new breakt...
Companies similar to Ocugen
Helsinki, Finland
Lumos Pharma
Transforming Lives with Rare Focus
Austin, United States
Hemera Biosciences LLC
Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-re...
Waltham, United States
RetinAI
Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials....
Bern, Switzerland
Track all Ocugen competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
PanOptica, Inc.
Empowering vision restoration through groundbreaking ophthalmic therapeutics.
United States
Inotek Pharmaceuticals
Innovative molecules addressing critical eye diseases for millions.
AsclepiX Therapeutics
Fraud Alert Regarding Third Party Employment Agencies
Baltimore, United States
Ocuphire Pharma
Restoring Vision and Clarity
Farmington Hills, United...
Coave Therapeutics
Coave therapeutics new brand for Horama
Paris, France
Precigen
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of ge...
Germantown, United States
bluebird bio
Pursuing curative gene therapies to give patients and their families more bluebird days.
Somerville, United States
Acumen Pharmaceuticals, Inc.
Forging a new path towards a safe and effective treatment for Alzheimer’s disease.
Charlottesville, United S...
About Ocugen
Ocugen, founded in 2013 and headquartered in the United States, is a biotechnology company dedicated to tackling major blindness diseases with innovative gene therapies. Through their unique modifier gene therapy platform, Ocugen aims to address the significant unmet needs of large patient populations using a gene-agno...
Development of Gene Therapies, Research and Development, Clinical Trial Management, Patient-Centric Solutions
Patients with Retinal Diseases, Healthcare Providers, Medical Researchers, Investors in Biotech Sector
Gene Therapy, Blindness Diseases, Ophthalmology, Clinical-stage Biopharmaceutical, Modifier Gene Therapy Platform, Inherited Retinal Disorders, COVID-19 Vaccine, Wet Age-related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Therapeutics, Biologics, Rare Diseases, Commercialization
B2B, B2C, B2D
Licensing, Product Sales
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Ocugen and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Ocugen on 9 Jun 2026. The 12 companies listed here were last checked between 26 Jul 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
